Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Smith & Nephew plc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.82, while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Smith & Nephew plc pays a 2.59% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| PDBC | SNN | |
|---|---|---|
52-Week High | $18.91 | $38.70 |
52-Week Low | $12.90 | $28.73 |
Market Cap | — | $12.71B |
Sector | — | Health |
Enterprise Value | — | $15.48B |
Dividend Yield | — | 2.59% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
